Clinical trials: Pioglitazone
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes
This trial is conducted in Africa, Asia, Europe, and the United States of America (USA). The aim of this clinical trial is to compare NN1250 (insulin degludec (IDeg)) with insulin glargine (IGlar) plus insulin aspart (IAsp)…
- Trial name
- BEGIN™ (NCT00972283)
- Testing
- insulin degludec, insulin glargine, insulin aspart
- Where
- 136 sites in United States, Bulgaria and 10 more
- Volunteers
- 1,006 people
- Sponsor
- Novo Nordisk A/S
Hepatitis
Treating Nonalcoholic Steatohepatitis With Pioglitazone
Nonalcoholic steatohepatitis (NASH) is a common liver disease that resembles alcoholic hepatitis but occurs in persons who drink little or no alcohol.
- Trial name
- NCT00062764
- Testing
- Actos (Pioglitazone)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type 2 Diabetes Mellitus
A 2 Year Trial of Patients With Type 2 Diabetes Focusing on Cardiovascular Diagnostics and Metabolic Control
The purposes of this study are: to investigate the extent of cardiovascular complications in a representative cohort (n=135) of adult patients with type 2 diabetes; to examine if modern non-invasive assessment can replace…
- Trial name
- NCT00133718
- Testing
- Combined lifestyle intervention and optimisation of pharmacological treatment
- Where
- Norway
- Volunteers
- 120 people
- Sponsor
- Asker & Baerum Hospital
COVID-19
The KIN-FAST Trial (KIN001 For Accelerated Symptoms Termination) in Non Hospitalized Patients Infected With SARS-CoV-2
Clinical trial on safety and efficacy of KIN001 in non-hospitalized patients with COVID-19.
- Trial name
- KIN-FAST (NCT05659459)
- Testing
- KIN001
- Where
- 8 sites in Germany, Switzerland
- Volunteers
- 17 people
- Sponsor
- Kinarus AG
Ketosis Prone Diabetes, Diabetic Ketoacidosis
Ketosis Prone Diabetes in African-Americans
Over 50% of obese African-Americans (AA) presenting with newly diagnosed, severe hyperglycemia and/or unprovoked diabetic ketoacidosis (DKA) display clinical, metabolic, and immunogenetic features of type 2 diabetes.
- Conditions
- Ketosis Prone Diabetes, Diabetic Ketoacidosis, Severe Hyperglycemia
- Trial name
- NCT00426413
- Testing
- pioglitazone
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Emory University
Diabetes Mellitus
A Double-blind, Parallel Group, Comparative Study of Coadministration AD-4833 and SYR-322
To evaluate the efficacy and safety of coadministration AD-4833 and SYR-322 in patients with diabetes mellitus.
- Trial name
- NCT01686711
- Testing
- AD-4833 15 mg, AD-4833 30 mg
- Where
- 25 sites in Japan
- Volunteers
- 207 people
- Sponsor
- Takeda
Diabetic, Myocardial Infarction
The Effect of Sitagliptin, Pioglitazone and Dapagliflozine on Myocardial Infarction in Diabetic Rats
The aim of the present study is to evaluate the prophylactic effect of Sitagliptin, Pioglitazone and Dapagliflozine on Isoprenaline induced myocardial infarction in type II diabetic rats.
- Trial name
- NCT07083232
- Testing
- standard normal diet, low dose Streptozotocin, Sitagliptin (Novartis, USA)
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Al-Azhar University
Type 2 Diabetes Mellitus
Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)
This study will examine the safety and efficacy of the addition of omarigliptin in Japanese participants with type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy and oral antihyperglycemic agent…
- Trial name
- NCT01697592
- Testing
- Omarigliptin
- Volunteers
- 585 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen for T2DM During Ramadan
This study aims to determine if the addition of Canagliflozin (Invokana™) therapy to monotherapy of metformin is more effective at achieving the double composite endpoint of a reduction in HbA1c (≥ 0.3%) and weight loss (≥1kg)…
- Trial name
- Can Do (NCT02694263)
- Testing
- Canagliflozin, Repaglinide, Pioglitazone
- Where
- 2 sites in United Kingdom
- Volunteers
- 25 people
- Sponsor
- University of Leicester
Diabetes Mellitus Type 2
Efficacy and Tolerability of MK0533 in Patients With Type 2 Diabetes (0533-005)
A study to evaluate the effectiveness and tolerability of MK0533 and pioglitazone in patients with type 2 diabetes mellitus.
- Trial name
- NCT00543959
- Testing
- MK0533, Comparator: pioglitazone
- Volunteers
- 346 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 1 Diabetes Mellitus
Dapagliflozin Plus Pioglitazone in T1DM
Purpose: To examine the effect of addition of combination therapy with dapagliflozin plus pioglitazone to insulin on glucose control and plasma ketone concentration in patients with type 1 diabetes (T1DM) Research Design: 120…
- Trial name
- NCT03878459
- Testing
- Pioglitazone 45 mg
- Where
- 3 sites in United States, Israel and 1 more
- Volunteers
- 120 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Myositis, Inclusion Body Myositis
Study of Pioglitazone in Sporadic Inclusion Body Myositis
A study looking at the effect of pioglitazone in skeletal muscle of patients with sporadic inclusion body myositis (sIBM).
- Conditions
- Myositis, Inclusion Body Myositis, Muscular Diseases, Musculoskeletal Disease
- Trial name
- NCT03440034
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Johns Hopkins University
Diabetes, Diabetes Mellitus, Type 2
Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes
This trial is conducted in the United States of America (USA). This trial will compare the changes in HbA1c after 26 weeks of inhaled insulin and pioglitazone combination therapy versus pioglitazone treatment alone.
- Trial name
- NCT00411892
- Testing
- pioglitazone, inhaled human insulin
- Where
- 110 sites in United States
- Volunteers
- 196 people
- Sponsor
- Novo Nordisk A/S
Friedreich's Ataxia
Effect of Pioglitazone Administered to Patients With Friedreich's Ataxia: Proof of Concept
Friedreich's ataxia (FA) is a rare progressive neurological disorder affecting approximately 1/30, 000 individuals. No treatment is presently available to counteract the neurodegeneration of this extremely severe disease.
- Trial name
- ACTFRIE (NCT00811681)
- Testing
- pioglitazone
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Healthy
Pharmacokinetic and Safety Study of Cenicriviroc and Pioglitazone, When Dosed Alone or in Combination
A single center, open-label, fixed sequence study to evaluate the pharmacokinetics (PK) of Cenicriviroc (CVC) administered with and without Pioglitazone (PGZ), and to evaluate the PK of PGZ administered with and without CVC.
- Trial name
- NCT02342067
- Testing
- Cenicriviroc, Pioglitazone
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Tobira Therapeutics, Inc.
Infertility, Female, Obesity
Mediators of Abnormal Reproductive Function in Obesity (MARO)
The study is seeking to understand how being overweight and obese makes women less fertile. The studies the investigators have done so far indicate that there is a hormone or other substance produced by fat that goes into the…
- Trial name
- MARO (NCT01817400)
- Testing
- Microdialysis, Vascepa - Fish Oil, Aspirin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Colorado, Denver
Type 2 Diabetes
Safety and Efficacy of Nateglinide in Patients With Type 2 Diabetes Already Taking Insulin Glargine, Metformin and/or Pioglitazone or Rosiglitazone
This study will assess the safety and efficacy of adding nateglinide to treatment with basal insulin glargine, metformin and/or thiazolidinedione (pioglitazone or rosiglitazone), for patients with type 2 diabetes who are not…
- Trial name
- NCT00402909
- Testing
- Nateglinide
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes
TriMaster: Study of a DPP4 Inhibitor, SGLT2 Inhibitor and Thiazolidinedione as Third Line Therapy in Patients With Type 2 Diabetes.
The aim of this project is to identify subgroups of patients with type 2 diabetes that respond well or poorly to particular drugs based on particular clinical characteristics such as their weight or kidney function, to enable…
- Trial name
- TriMaster (NCT02653209)
- Testing
- Sitagliptin - DPP4i, Canagliflozin - SGLT2i, Pioglitazone - TZD
- Where
- United Kingdom
- Volunteers
- 525 people
- Sponsor
- Royal Devon and Exeter NHS Foundation Trust
Type II Diabetes Mellitus
A Study of Different Doses of Sitagliptin (MK-0431) in Participants With Type 2 Diabetes Mellitus (MK-0431-014)
A study of different doses of MK-0431 in participants with type 2 diabetes mellitus. There have been 3 extensions to the base study (Extension 1: up to Week 52, Extension 2: up to Week 106, and Extension 3: up to Week 158).
- Trial name
- NCT00481663
- Testing
- Sitagliptin, Metformin, Rescue
- Volunteers
- 555 people
- Sponsor
- Merck Sharp & Dohme LLC
ANCA Associated Vasculitis, Rapidly Progressive Glomerulonephritis
A Trial to Evaluate the Efficacy of Pioglitazone to Promote Renal Tolerance in ANCA-associated Vasculitis - RENATO Trial
The RENATO trial is a multicenter randomized controlled trial that evaluates the efficacy of pioglitazone to improve renal outcomes in ANCA-associated vasculitis.
- Conditions
- ANCA Associated Vasculitis, Rapidly Progressive Glomerulonephritis, Crescentic Glomerulonephritis
- Trial name
- RENATO (NCT05946564)
- Testing
- Pioglitazone (ACTOS®)
- Where
- 25 sites in France
- Volunteers
- 126 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris